Difference between revisions of "CT Angiography Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
m
m
 
(47 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
'''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
+
'''Co-chairs''': Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
−
'''RSNA Staff Support''': Julie Lisiecki
+
 
 
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]
 
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]
  
Line 8: Line 8:
 
'''Recent Call Summaries:'''
 
'''Recent Call Summaries:'''
  
−
*[[Media: 2019 04 08 QIBA CT Angiography_FINAL-b.pdf | April 8, 2019]]
+
*[[Media:2023_06-27_QIBA_CT_Angiography-FINAL.pdf| June 27, 2023]]
−
*[[Media: 2019 03 11 QIBA CT Angiography_FINAL-b.pdf | March 11, 2019]]
+
*[[Media:2023 03 28 QIBA CT Angiography FINAL.pdf| March 28, 2023]]
−
*[[Media: 2019 02 25 QIBA CT Angiography_FINAL.pdf | February 25, 2019]]
+
*[[Media:2023 03 14 QIBA CT Angiography FINAL.pdf| March 14, 2023]]
−
*[[Media: 2019 02 11 QIBA CT Angiography_FINAL.pdf | February 11, 2019]]
+
*[[Media:2023 02 14 QIBA CT Angiography FINAL.pdf| February 14, 2023]]
−
*[[Media: 2019 01 28 QIBA CT Angiography_FINAL.pdf | January 28, 2019]]
 
−
*[[Media: 2019 01 14 QIBA CT Angiography_FINAL.pdf | January 14, 2019]]
 
−
*[[Media: 2018 12 17 QIBA CT Angiography_FINAL.pdf | December 17, 2018]]
 
  
 
'''''[[CT Angiography Call Summaries Archive]]'''''
 
'''''[[CT Angiography Call Summaries Archive]]'''''
Line 27: Line 24:
 
==Profile Development==
 
==Profile Development==
  
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-26.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 26, 2019]]
+
*[[Media:QIBA CTA Profile as of 2023-Feb-16.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-11.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 11, 2019]]
+
*[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:2019_01-31_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 31, 2019]]
+
*[[Media:QIBA CTA Field Test Checklist.xlsx|QIBA Atherosclerosis Checklists]]
−
*[[Media:2019_01-14_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 14, 2019]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-11-27-full.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:2018_12-17_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | December 17, 2018]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-11-27.PDF| QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)]]
 +
*[[Media:CTA Comments 2019-11-27.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
 +
 
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-10-30.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:CTA Comments 2019-10-30.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
 +
 
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-09-09b.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:CTA Comments 2019-09-09.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
 +
 
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-08-26.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:CTA Comments 2019-08-26.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
 +
 
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-08-12.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:CTA Comments 2019-08-12.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
 +
 
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-07-29.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:CTA Comments 2019-07-29.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-02-26.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-02-11.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:2019 01-31 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:2019 01-14 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:2018 12-17 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
  
 
'''''[[Atherosclerosis Biomarkers Profile Draft Archive]]'''''
 
'''''[[Atherosclerosis Biomarkers Profile Draft Archive]]'''''
Line 38: Line 56:
  
 
==Reference Materials==
 
==Reference Materials==
−
*[[Media:Biomarkers Selection Criteria.pdf | QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler}]] ''March 27, 2018'' (PDF)
+
*[[Media:Biomarkers Selection Criteria.pdf| QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler}]] ''March 27, 2018'' (PDF)
  
 
==Conformance Materials==
 
==Conformance Materials==

Latest revision as of 18:40, 21 December 2023

Co-chairs: Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT


Meetings

Recent Call Summaries:

CT Angiography Call Summaries Archive

Project Snapshot - CT Angiography

The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).

Excerpt from the biomarker committee submission form:

The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.

Profile Development

Atherosclerosis Biomarkers Profile Draft Archive

Groundwork Projects

Reference Materials

Conformance Materials

Retrieved from "https://qibawiki.rsna.org/index.php?title=CT_Angiography_Biomarker_Ctte&oldid=19476"